Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 9/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.48 |
| ▸ | MET | P08581 | 9/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073787 | 1.00 | INSR (0.48) | INSRALKMETAURKAMAPK8 | |
| SCHEMBL30266367 | 1.00 | INSR (0.48) | INSRALKMETAURKAMAPK8 | |
| SCHEMBL25834891 | 0.91 | MET (0.56) | INSRALKMETMAPK8MAPK9 | |
| SCHEMBL24073743 | 0.91 | MET (0.56) | INSRALKMETMAPK8MAPK9 | |
| SCHEMBL30266417 | 0.89 | INSR (0.49) | INSRALKMETSLC2A1AXL | |
| SCHEMBL24073791 | 0.89 | INSR (0.49) | INSRALKMETSLC2A1AXL | |
| SCHEMBL25835411 | 0.89 | INSR (0.49) | INSRALKMETSLC2A1AXL | |
| SCHEMBL24073798 | 0.84 | MAPK9 (0.66) | INSRALKMETMAPK8MAPK9 | |
| SCHEMBL24073734 | 0.84 | MAPK9 (0.66) | INSRALKMETMAPK8MAPK9 | |
| SCHEMBL24073380 | 0.83 | MET (0.56) | INSRALKMETMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | INSR 1450/4885ALK 87/4885MET 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.